Midazolam ( DrugBank: Midazolam )
12 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
| 3 | Spinal muscular atrophy | 1 |
| 6 | Parkinson disease | 2 |
| 13 | Multiple sclerosis/Neuromyelitis optica | 2 |
| 21 | Mitochondrial disease | 1 |
| 46 | Malignant rheumatoid arthritis | 5 |
| 70 | Spinal stenosis | 1 |
| 96 | Crohn disease | 3 |
| 97 | Ulcerative colitis | 2 |
| 231 | Alpha-1-antitrypsin deficiency | 1 |
| 272 | Fibrodysplasia ossificans progressiva | 1 |
| 298 | Hereditary pancreatitis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02655614 (ClinicalTrials.gov) | May 31, 2016 | 7/1/2016 | A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis | A Phase I, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Single- and Multiple-Ascending-Dose Study to Determine Initial Safety, Tolerability, and Pharmacokinetics of GDC-0134 in Patients With Amyotrophic Lateral Sclerosis | Amyotrophic Lateral Sclerosis | Drug: GDC-0134;Drug: Placebo;Drug: Rabeprazole;Drug: Midazolam;Drug: Caffeine | Genentech, Inc. | NULL | Completed | 18 Years | N/A | All | 54 | Phase 1 | United States;Canada;Netherlands |
3. Spinal muscular atrophy
Clinical trials : 217 / Drugs : 149 - (DrugBank : 33) / Drug target genes : 54 - Drug target pathways : 80
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03988907 (ClinicalTrials.gov) | June 18, 2019 | 14/6/2019 | A Drug-drug Interaction Study With Risdiplam Multiple Dose and Midazolam in Healthy Participants | A Phase I, 2-Part, Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Risdiplam and the Effect of Risdiplam on the Pharmacokinetics of Midazolam Following Oral Administration in Healthy Participants | Spinal Muscular Atrophy | Drug: Risdiplam;Drug: Midazolam | Hoffmann-La Roche | NULL | Completed | 18 Years | 55 Years | All | 35 | Phase 1 | United States |
6. Parkinson disease
Clinical trials : 2,298 / Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04912115 (ClinicalTrials.gov) | October 5, 2021 | 25/5/2021 | Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia | A Multi-Center, Phase II, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects With Parkinson's Disease | Dyskinesias;Movement Disorders;Central Nervous System Diseases;Nervous System Diseases;Neurologic Manifestations | Drug: Ketamine;Drug: Midazolam | PharmaTher Inc. | NULL | Active, not recruiting | 30 Years | 85 Years | All | 30 | Phase 2 | United States |
| 2 | NCT03970798 (ClinicalTrials.gov) | May 22, 2019 | 23/5/2019 | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin | Parkinson's Disease | Drug: Midazolam;Drug: Caffeine;Drug: Rosuvastatin;Drug: KW-6356 | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 50 | Phase 1 | Japan |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03500289 (ClinicalTrials.gov) | August 10, 2018 | 4/4/2018 | Ketamine for Treatment of MS Fatigue | Ketamine for Treatment of Multiple Sclerosis-related Fatigue | Multiple Sclerosis;Fatigue | Drug: Ketamine;Drug: Midazolam | Johns Hopkins University | National Multiple Sclerosis Society | Completed | 18 Years | 65 Years | All | 18 | Phase 1/Phase 2 | United States |
| 2 | NCT01462318 (ClinicalTrials.gov) | November 2011 | 14/7/2011 | An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis | A Multicenter, Single-Arm, Open-Label Study to Evaluate the Immunogenicity and Pharmacokinetics of BIIB019, Daclizumab High Yield Process (DAC HYP), Prefilled Syringe Administered by Subcutaneous Injection in Subjects With Relapsing-Remitting Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Drug: Midazolam;Other: Caffeine;Drug: S-warfarin;Other: Vitamin K;Drug: Omeprazole;Drug: Dextromethorphan;Biological: BIIB019 (Daclizumab) | Biogen | NULL | Completed | 18 Years | 65 Years | All | 133 | Phase 3 | United States;Czech Republic;Hungary;Poland;Russian Federation |
21. Mitochondrial disease
Clinical trials : 33 / Drugs : 42 - (DrugBank : 32) / Drug target genes : 47 - Drug target pathways : 67
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04643249 (ClinicalTrials.gov) | November 10, 2020 | 13/11/2020 | Drug-drug Interaction Study of KL1333 in Healthy Subjects | A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects | Mitochondrial Disease | Drug: KL1333;Drug: Flurbiprofen;Drug: Dextromethorphan;Drug: Bupropion;Drug: Midazolam injection;Drug: Omeprazole;Drug: Caffeine;Drug: Repaglinide | Abliva AB | NULL | Completed | 18 Years | 65 Years | All | 14 | Phase 1 | United Kingdom |
46. Malignant rheumatoid arthritis
Clinical trials : 4,325 / Drugs : 2,671 - (DrugBank : 417) / Drug target genes : 187 - Drug target pathways : 224
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04246762 (ClinicalTrials.gov) | April 6, 2021 | 27/1/2020 | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 | A Phase 1, Open-label, Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19, and CYP3A4 | Rheumatoid Arthritis | Drug: Olokizumab;Drug: Omeprazole;Drug: Caffeine;Drug: Warfarin+ Vitamin K;Drug: Midazolam | R-Pharm International, LLC | IQVIA RDS Ireland Ltd;Thermo Fisher Scientific | Recruiting | 18 Years | 70 Years | All | 15 | Phase 1 | Bulgaria;Moldova, Republic of |
| 2 | NCT03131973 (ClinicalTrials.gov) | May 13, 2017 | 25/4/2017 | Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin | Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants | Rheumatoid Arthritis | Drug: BMS-986195;Drug: Methotrexate;Drug: Leucovorin;Drug: Caffeine;Drug: Montelukast;Drug: Flurbiprofen;Drug: Omeprazole;Drug: Midazolam;Drug: Digoxin;Drug: Pravastatin | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | All | 26 | Phase 1 | United States |
| 3 | NCT02762123 (ClinicalTrials.gov) | May 2016 | 3/5/2016 | A Study to Assess the Effect of BMS-986142 on Pharmacokinetics (PK) of Probe Substrates | Effects of Concomitant Administration of BMS-986142 on the Single-dose Pharmacokinetics of Probe Substrates for CYP2C8, CYP2C9, CYP2C19, CYP3A4, and P-gp in Healthy Subjects | Rheumatoid Arthritis | Drug: BMS-986142 200mg;Drug: BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin);Drug: BMS-986142 350mg | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | Both | 28 | Phase 1 | United States |
| 4 | NCT02456844 (ClinicalTrials.gov) | May 2015 | 27/5/2015 | Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients | Effects of BMS-986142 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates Montelukast (CYP2C8), Flurbiprofen (CYP2C9), Midazolam (CYP3A4), Digoxin (P-gp), and Pravastatin (OATP1B1) in Healthy Subjects | Rheumatoid Arthritis | Drug: Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142;Drug: Methotrexate, Leucovorin and BMS-986142 | Bristol-Myers Squibb | NULL | Completed | 18 Years | 50 Years | Both | 24 | Phase 1 | NULL |
| 5 | NCT01636557 (ClinicalTrials.gov) | October 11, 2012 | 6/7/2012 | A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis | A Phase I, Open-label, Drug Interaction Study to Evaluate the Effect of a Single-dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Subjects With Rheumatoid Arthritis | Arthritis, Rheumatoid | Drug: Sirukumab;Drug: Midazolam;Drug: Warfarin;Drug: Vitamin K;Drug: Omeprazole;Drug: Caffeine | Janssen Research & Development, LLC | NULL | Completed | 18 Years | 65 Years | All | 12 | Phase 1 | Germany;Korea, Republic of;Moldova, Republic of;South Africa |
70. Spinal stenosis
Clinical trials : 96 / Drugs : 203 - (DrugBank : 60) / Drug target genes : 66 - Drug target pathways : 89
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01275547 (ClinicalTrials.gov) | January 2011 | 11/1/2011 | The Analgesic Effect of Combined Treatment With Intranasal S-ketamine and Intranasal Midazolam | The Analgesic Effect of Combined Treatment With Intranasal S-Ketamine and Intranasal Midazolam Compared With Morphine Patient Controlled Analgesia in Spinal Surgery Patients | Analgesia, Patient-controlled;Spinal Stenosis | Drug: s-ketamine & midazolam;Drug: Morphine PCA | University Hospital, Basel, Switzerland | NULL | Completed | 18 Years | N/A | Both | 22 | Phase 2/Phase 3 | Switzerland |
96. Crohn disease
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03358706 (ClinicalTrials.gov) | February 2, 2018 | 27/11/2017 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis. | Crohn Disease;Ulcerative Colitis | Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | 75 Years | All | 57 | Phase 1 | United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden |
| 2 | NCT02760615 (ClinicalTrials.gov) | November 1, 2016 | 2/5/2016 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease | Colitis, Ulcerative;Crohn Disease | Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab | Takeda | NULL | Withdrawn | 18 Years | 55 Years | All | 0 | Phase 4 | United States |
| 3 | NCT01489943 (ClinicalTrials.gov) | September 19, 2011 | 1/12/2011 | A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | A Single Centre, Single Sequence, Open-Label, Repeat-Dose Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects | Crohn's Disease | Drug: GSK1605786 500 mg;Drug: Midazolam 3 mg;Drug: Pioglitazone 15 mg;Drug: Omeprazole 40 mg;Drug: Rosuvastatin 10 mg | GlaxoSmithKline | NULL | Completed | 18 Years | 55 Years | All | 24 | Phase 1 | United States |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03358706 (ClinicalTrials.gov) | February 2, 2018 | 27/11/2017 | A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis | A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis. | Crohn Disease;Ulcerative Colitis | Drug: Ustekinumab IV Infusion;Drug: Ustekinumab SC Injection;Drug: Midazolam 2 mg;Drug: Warfarin 10 mg;Drug: Vitamin K 10 mg;Drug: Omeprazole 20 mg;Drug: Dextromethorphan 30 mg;Drug: Caffeine 100 mg | Janssen Research & Development, LLC | NULL | Recruiting | 18 Years | 75 Years | All | 57 | Phase 1 | United States;Belgium;Germany;United Kingdom;Austria;Denmark;Sweden |
| 2 | NCT02760615 (ClinicalTrials.gov) | November 1, 2016 | 2/5/2016 | Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study | An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease | Colitis, Ulcerative;Crohn Disease | Drug: Caffeine;Drug: Losartan;Drug: Omeprazole;Drug: Dextromethorphan;Drug: Midazolam;Drug: Vedolizumab | Takeda | NULL | Withdrawn | 18 Years | 55 Years | All | 0 | Phase 4 | United States |
231. Alpha-1-antitrypsin deficiency
Clinical trials : 89 / Drugs : 89 - (DrugBank : 16) / Drug target genes : 35 - Drug target pathways : 47
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01810458 (ClinicalTrials.gov) | October 2013 | 6/3/2013 | Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD) | Clinical Predictors and Epigenetic Markers for Liver Fibrosis in Alpha-1 Antitrypsin Deficiency | Liver Fibrosis;Alpha-1 Antitrypsin Deficiency;AAT Deficiency;AATD | Device: Abdominal ultrasound;Procedure: History and physical;Procedure: Intravenous catheter;Procedure: Blood draw;Other: Liver questionnaire;Procedure: Liver Biopsy;Drug: Midazolam;Drug: Fentanyl;Drug: Lidocaine;Drug: Acetaminophen;Drug: Lorazepam;Drug: Oxycodone/Acetaminophen;Drug: Ondansetron | University of Florida | NULL | Completed | 18 Years | 70 Years | All | 109 | United States |
272. Fibrodysplasia ossificans progressiva
Clinical trials : 40 / Drugs : 36 - (DrugBank : 6) / Drug target genes : 27 - Drug target pathways : 95
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04829773 (ClinicalTrials.gov) | January 3, 2019 | 1/4/2021 | Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | An Open-Label Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects | Fibrodysplasia Ossificans Progressiva | Drug: Palovarotene;Drug: midazolam | Clementia Pharmaceuticals Inc. | NULL | Completed | 18 Years | 55 Years | All | 48 | Phase 1 | United States |
298. Hereditary pancreatitis
Clinical trials : 98 / Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-003357-17-DK (EUCTR) | 01/11/2013 | 04/11/2013 | The Ketamine - a novel approach to treating painful chronic pancreatitis. | RESET TrialA randomized, double-blinded, single-centre, parallel-group, placebo-controlled, prospective trial of S-ketamine for pain treatment in chronic pancreatitis (RESET trial) - RESET Trial | Chronic Pancreatitis MedDRA version: 17.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 100000004856 MedDRA version: 17.1;Level: HLT;Classification code 10033646;Term: Acute and chronic pancreatitis;System Organ Class: 100000004856;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: S-Ketamin Product Name: S-ketamin Trade Name: Midazolam Product Name: Midazolam | Prof. Asbjørn Mohr Drewes | NULL | Not Recruiting | Female: yes Male: yes | 60 | Phase 4 | Denmark |